Progress report
Yüklə 320,3 Kb.
|
- Bu səhifədəki naviqasiya:
- Presentations mentioning the Network
Annex 1 Overview of meetings where the Network was/will be presented or mentioned Presentations focusing on the Action/discussing the Action (for at least 5 minutes) Presenter: Annemieke Aartsma-Rus Date: 15-17 April 2013 Location: Dublin, Ireland Meeting: International conference of the International Rare Disease Research Consortium (IRDiRC) Audience type: Scientists, clinicians and patient representatives Audience size: ~ 300 Title talk: Antisense-mediated exon skipping – Applying lessons learnt from Duchenne muscular dystrophy to other rare diseases
Date: 17 May 2013 Location: Salt Lake City, Utah, USA Meeting: ASGCT satellite meeting of the Gene and Cell Therapy Consortium Audience type: Scientists and clinicians Audience size: ~100 Title talk: Networking – the TREAT-NMD paradigm
Date: 13 Sept 2013 Location: Leiden, the Netherlands Meeting: Gene therapy workshop of the Dutch Organisation of Bone Marrow Transplantation Audience type: scientists and clinicians Audience size: ~150 Title talk: Opportunities of antisense-mediated exon skipping
Date: 16-19 October 2013 Location: San Sebastian, Spain Meeting: International Myotonic Dystrophy Consortium Audience type: Scientists and Clinicians Audience size: ~200-300 Title poster: Networking towards clinical implementation of antisense-mediated exon skipping
Date: 23-26 October 2013 Location: Turin, Italy Meeting: Rare Disease symposium of the Italian Pharmacological Society Audience type: Pharmacologists Audience size: ~100 Title talk: Antisense-mediated exon skipping – a therapeutic approach with potential for DMD and other rare diseases
Date: 29 October – 1 November Location: Newcastle, UK Meeting: TREAT-NMD symposium Audience type: Scientists, clinicians, industry representatives, patient representatives Audience size: ~ 300-400 Title talk: Joint research and regulatory interaction
Date: 17 December 2013 Location: Bonn, Germany Lecture: Leiter des Schwerpunkts Klinische Neuroonkolgie Lecture Audience type: Clinicians and scientists Audience size: ~ 100 Title talk: Antisense-mediated exon skipping for Duchenne muscular dystrophy and other neurological disorders
Date: 21-23 February 2014 Location: Rome, Italy Meeting: Italian Duchenne Parent Project Onlus Audience type: parents, patients, scientists, clinicians, industry representatives Audience size: ~400 Title talk: Preclinical exon skipping studies
Date: 24-26 February 2014 Location: Heidelberg, Germany Meeting: RD-Connect, NEUROMICS and EURENOMICS joint progress meeting Audience type: scientists, clinicians Audience size: ~500 Title talk: Antisense-mediated exon skipping for DMD and other rare diseases
Date: 13-14 March 2014 Location: Lunteren, the Netherlands Meeting: Annual meeting of the Dutch Society of Gene and Cell Therapy Audience type: clinicians, scientists, industry representatives Audience size: ~ 100 Title talk: Antisense-mediated exon skipping: An approach with therapeutic potential for DMD and other diseases
Date: 27-28 March 2014 Location: Porto, Portugal Meeting: Genetics Conference Audience type: geneticists Audience size: ~200 Title talk: Antisense-mediated exon skipping for Duchenne muscular dystrophy – clinical trials and beyond
Date: April 21-24 2013 Location: Washington DC, US Meeting: Muscular Dystrophy Association Scientific Conference Audience type: scientists, clinicians and patient representatives Audience size: ~500 Title talk: What we have learned from clinical trials to date
Date: April 24 2013 Location: Washington DC, US Lecture at Children’s National Medical Center Audience type: scientists and clinicians Audience size: 100 Title presentation: the development of antisense-mediated exon skipping for DMD
Date: 11-13 June 2013 Location: Paris, France Meeting: SPATAX Audience type: scientists, clinicians and patients Audience size: 200 Title presentation: Using antisense oligonucleotides to reduce or modify the disease causing proteins in autosomal dominant spinocerebellar ataxis
Date: August 22 2013 Location: Tanjin University, China Lecture at Tanjin University Audience type: scientists Audience size: 20 Title presentation: Antisense-mediated exon skipping for DMD
Date: September 3-6 2013 Location: Barcelona, Spain Meeting: International Congress of Inborn Errors of Metabolism Audience type: Scientists and Clinicians Audience size: ~500 Title poster presentation: In vivo effect of splice modulating antisense oligonucleotides: generation of hyperphenylalaninemia mice as model
Date: 7 September 2013 Location: Veldhoven, the Netherlands Meeting: Muscle Congress of the Dutch Neuromuscular Patient Organisation Audience type: Patients and parents Audience size: ~80 Title talk: Overview of medication trials in Duchenne muscular dystrophy
Date: 30-31 October 2013 Location: Newcastle UK Meeting: TREAT-NMD symposium Audience type: Scientists, clinicians, industry representatives, patient representatives Audience size: ~ 300-400 Title talk: Emerging therapies for SMA
Date: 1-2 November 2013 Location: Athens, Greece Meeting: Mediterranean Society of Myology Audience type: Scientists, clinicians Audience size: ~ 200 Title talk: Genetic therapies in muscular dystrophies
Date: November 7 2013 Location: Helsinki, Finland Meeting: Annual meeting of the Finish Society of Pediatric Neurology in memory of Martha Donner Audience type: Clinicians Audience size: ~ 200 Title talk: Preclinical development of antisense-mediated exon skipping for DMD and other neurologic diseases
Date: November 20-22 2013 Location: Cardiff, UK Meeting: Cardiovascular genetics symposium Audience type: Cardiologists, clinical geneticists Audience size: ~ 400-500 Title talk: Antisense-mediated exon skipping for Duchenne muscular dystrophy
Date: January 11, 2014 Location: Chennai, India Meeting: Myocon Audience type: clinicians, researchers, parents Audience size: ~ 200-300 Title talk: Future directions of antisense-mediated exon skipping for Duchenne muscular dystrophy
Date: May 20-24 2014 Location: Washington DC USA Meeting: American Society of Gene and Cell Therapy Audience type: Scientists and Clinicians Audience size: ~1000 Title oral or poster presentation: A sensitive assay system to test antisense oligonucleotides for splice suppression therapy in mouse Yüklə 320,3 Kb. Dostları ilə paylaş:
|